Halozyme Therapeutics Inc (HALO) — Quality & forensics
As of 2026-09-24 — refreshed nightly. Closelook readings from an investment research diary, not ratings or advice.
The Closelook module scores
- Valuation 45
- Quality 94
- Growth 77
- Balance sheet 71
- Cash quality 63
- Capital allocation 62
- Momentum 96
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.
Continue: the HALO chart & overview · the earnings record
FAQ · from the current data · as of 2026-09-24
Quick answers
What is Halozyme Therapeutics Inc's Closelook quality reading?
The composite reads 74/100 across 7 modules, as of 2026-09-24: valuation 45, quality 94, growth 77, balance sheet 71, cash quality 63, capital allocation 62, momentum 96. Closelook scores are research diary readings, not ratings or investment advice.
What is Halozyme Therapeutics Inc's Altman Z-Score?
5.05, which sits in the safe zone (above 2.99) as of 2026-09-24. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is Halozyme Therapeutics Inc's Piotroski F-Score?
5 of 9, as of 2026-09-24. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does Halozyme Therapeutics Inc's Beneish M-Score indicate?
-2.73 — below the −1.78 manipulation-risk threshold, as of 2026-09-24. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelook universe
then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- BION.SW BB Biotech AGindustry
- ARGX.BR Argen-Xindustry
- ARGX argenx NV ADRindustry
- ONC BeiGene, Ltd.industry
- KRYS Krystal Biotech Incindustry
- CAI Caris Life Sciences, Inc. Common Stockindustry
- MRNA Moderna Incindustry
- TWST Twist Bioscience Corpindustry
- DNA Ginkgo Bioworks Holdingsindustry
- ONT.L Oxford Nanopore Technologies Ltdindustry
- RXRX Recursion Pharmaceuticals Incindustry
- MRVI Maravai Lifesciences Holdings Incindustry
- TGTX TG Therapeutics Incindustry
- EXEL Exelixis Incindustry
- CRSP Crispr Therapeutics AGindustry
- INCY Incyte Corporationindustry
- TECH Bio-Techne Corpindustry
- RPRX Royalty Pharma Plcindustry
- PCVX Vaxcyte Incindustry
- BMRN Biomarin Pharmaceutical Incindustry